You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRosiglitazone
Accession NumberDB00412  (APRD00403)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionRosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.
Structure
Thumb
Synonyms
(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
Rosiglitazon
Rosiglitazona
Rosiglitazone
Rosiglitazonum
External Identifiers
  • BRL 49653 C
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Avandiatablet, film coated2 mg/1oralPhysicians Total Care, Inc.2005-05-13Not applicableUs
Avandiatablet, film coated2 mg/1oralGlaxo Smith Kline Llc2011-05-25Not applicableUs
Avandiatablet4 mgoralGlaxosmithkline Inc2000-03-21Not applicableCanada
Avandiatablet, film coated4 mg/1oralCardinal Health1999-05-29Not applicableUs
Avandiatablet, film coated8 mg/1oralGlaxo Smith Kline Llc2011-05-252016-04-03Us
Avandiatablet8 mgoralGlaxosmithkline Inc2000-03-21Not applicableCanada
Avandiatablet, film coated4 mg/1oralPhysicians Total Care, Inc.2006-02-07Not applicableUs
Avandiatablet, film coated8 mg/1oralCardinal Health1999-05-28Not applicableUs
Avandiatablet, film coated8 mg/1oralPhysicians Total Care, Inc.2001-05-09Not applicableUs
Avandiatablet2 mgoralGlaxosmithkline Inc2000-03-21Not applicableCanada
Avandia 2mgtablet, film coated2 mg/1oralGlaxo Smith Kline Llc2011-05-25Not applicableUs
Avandia 4mgtablet, film coated4 mg/1oralGlaxo Smith Kline Llc2011-05-25Not applicableUs
Avandia 8mgtablet, film coated8 mg/1oralGlaxo Smith Kline Llc2011-05-25Not applicableUs
Dom-rosiglitazonetablet2 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-rosiglitazonetablet4 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-rosiglitazonetablet8 mgoralDominion PharmacalNot applicableNot applicableCanada
Mylan-rosiglitazonetablet2 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-rosiglitazonetablet4 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-rosiglitazonetablet8 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PHL-rosiglitazonetablet2 mgoralPharmel IncNot applicableNot applicableCanada
PHL-rosiglitazonetablet4 mgoralPharmel IncNot applicableNot applicableCanada
PHL-rosiglitazonetablet8 mgoralPharmel IncNot applicableNot applicableCanada
PMS-rosiglitazonetablet8 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-rosiglitazonetablet2 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-rosiglitazonetablet4 mgoralPharmascience IncNot applicableNot applicableCanada
Teva-rosiglitazonetablet4 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-rosiglitazonetablet8 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-rosiglitazonetablet2 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-rosiglitazonetablet2.0 mgoralApotex IncNot applicableNot applicableCanada
Apo-rosiglitazonetablet4.0 mgoralApotex IncNot applicableNot applicableCanada
Apo-rosiglitazonetablet8.0 mgoralApotex IncNot applicableNot applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AvandiaFilm-coated tablet4 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet2 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet4 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet2 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet4 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet8 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet2 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet8 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet4 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet4 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet8 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet2 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet8 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet4 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet8 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet4 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
AvandiaFilm-coated tablet2 mgOral useSmith Kline Beecham Plc2000-07-11Not applicableEu
International Brands
NameCompany
BlutabWerrick
DH-RosidiaHasan
DiabenElea
DiaglinexFarmindustria
GaudilCraveri
GliximinaDenver
NaidiHisun
RogelinTorrent
RoglitGedeon Richter
RomerolDrug International
RositDelta
RosixGarmisch
RossiniTrima
SensulinSquare
Sheng AoHengrui
Sheng MinShengJiTang Pharmaceutical
Brand mixtures
NameLabellerIngredients
AvandametGlaxo Smith Kline Llc
AvandarylGlaxo Smith Kline Llc
PMS-rosiglitazone-metforminPharmascience Inc
Salts
Name/CASStructureProperties
Rosiglitazone Maleate
155141-29-0
Thumb
  • InChI Key: SUFUKZSWUHZXAV-BTJKTKAUNA-N
  • Monoisotopic Mass: 473.125670795
  • Average Mass: 473.499
DBSALT000153
Categories
UNII05V02F2KDG
CAS number122320-73-4
WeightAverage: 357.427
Monoisotopic: 357.114712179
Chemical FormulaC18H19N3O3S
InChI KeyInChIKey=YASAKCUCGLMORW-UHFFFAOYNA-N
InChI
InChI=1/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
IUPAC Name
5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
SMILES
CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Dialkylarylamine
  • Phenol ether
  • Thiazolidinedione
  • Aminopyridine
  • Alkyl aryl ether
  • Imidolactam
  • Pyridine
  • Heteroaromatic compound
  • Thiazolidine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Thioether
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationRosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
PharmacodynamicsWhen rosiglitazone is used as monotherapy, it is associated with increases in total cholesterol, LDL, and HDL. It is also associated with decreases in free fatty acids. Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time.
Mechanism of actionRosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.
Related Articles
AbsorptionThe absolute bioavailability of rosiglitazone is 99%. Peak plasma concentrations are observed about 1 hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours). These changes are not likely to be clinically significant; therefore, rosiglitazone may be administered with or without food. Maximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range.
Volume of distribution
  • 17.6 L [oral volume of distribution Vss/F]
  • 13.5 L [population mean, pediatric patients]
Protein binding99.8% bound to plasma proteins, primarily albumin.
Metabolism

Hepatic. Rosiglitazone is extensively metabolized in the liver to inactive metabolites via N-demethylation, hydroxylation, and conjugation with sulfate and glucuronic acid. In vitro data have shown that Cytochrome (CYP) P450 isoenzyme 2C8 (CYP2C8) and to a minor extent CYP2C9 are involved in the hepatic metabolism of rosiglitazone.

SubstrateEnzymesProduct
Rosiglitazone
N-DesmethylrosiglitazoneDetails
Rosiglitazone
para-HydroxyrosiglitazoneDetails
Rosiglitazone
ortho-HydroxyrosiglitazoneDetails
Rosiglitazone
Not Available
N-Despyridinyl rosiglitazoneDetails
N-Desmethylrosiglitazone
Not Available
N-Desmethyl-ortho-hydroxy rosiglitazoneDetails
ortho-Hydroxyrosiglitazone
Not Available
N-Desmethyl-ortho-hydroxy rosiglitazoneDetails
N-Desmethylrosiglitazone
Not Available
N-Desmethyl-para-hydroxy rosiglitazoneDetails
para-Hydroxyrosiglitazone
Not Available
N-Desmethyl-para-hydroxy rosiglitazoneDetails
N-Desmethyl-ortho-hydroxy rosiglitazone
Not Available
N-Desmethyl-ortho-O-sulfate rosiglitazoneDetails
ortho-Hydroxyrosiglitazone
Not Available
ortho-O-Glucuronide rosiglitazoneDetails
ortho-Hydroxyrosiglitazone
Not Available
ortho-O-Sulfate rosiglitazoneDetails
N-Desmethylrosiglitazone
Not Available
N-Desmethyl glucuronide rosiglitazoneDetails
para-Hydroxyrosiglitazone
Not Available
para-O-Glucuronide rosiglitazoneDetails
para-Hydroxyrosiglitazone
Not Available
para-O-Sulfate rosiglitazoneDetails
N-Desmethyl-para-hydroxy rosiglitazone
Not Available
N-Desmethyl para-O-sulfate rosiglitazoneDetails
Rosiglitazone
Not Available
Phenoxyacetic acid derivative of rosiglitazoneDetails
Route of eliminationFollowing oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.
Half life3-4 hours (single oral dose, independent of dose)
Clearance
  • Oral clearance (CL) = 3.03 ± 0.87 L/hr [1 mg Fasting]
  • Oral CL = 2.89 ± 0.71 L/hr [2 mg Fasting]
  • Oral CL = 2.85 ± 0.69 L/hr [8 mg Fasting]
  • Oral CL = 2.97 ± 0.81 L/hr [8 mg Fed]
  • 3.15 L/hr [Population mean, Pediatric patients]
ToxicitySide effects include fluid retention, congestive heart failure (CHF), liver disease
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Rosiglitazone Metabolism PathwayDrug metabolismSMP00653
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9861
Blood Brain Barrier+0.8994
Caco-2 permeable-0.5451
P-glycoprotein substrateSubstrate0.6535
P-glycoprotein inhibitor INon-inhibitor0.5274
P-glycoprotein inhibitor IINon-inhibitor0.6289
Renal organic cation transporterNon-inhibitor0.5203
CYP450 2C9 substrateNon-substrate0.7418
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5744
CYP450 1A2 substrateInhibitor0.5391
CYP450 2C9 inhibitorInhibitor0.5783
CYP450 2D6 inhibitorNon-inhibitor0.846
CYP450 2C19 inhibitorInhibitor0.5884
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7213
Ames testNon AMES toxic0.687
CarcinogenicityNon-carcinogens0.9465
BiodegradationNot ready biodegradable0.8635
Rat acute toxicity2.4515 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8055
hERG inhibition (predictor II)Non-inhibitor0.7768
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sb pharmco puerto rico inc
  • Glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
Tabletoral2.0 mg
Tabletoral4.0 mg
Tabletoral8.0 mg
Tabletoral
Tablet, film coatedoral
Film-coated tabletOral use2 mg
Film-coated tabletOral use4 mg
Film-coated tabletOral use8 mg
Tabletoral2 mg
Tabletoral4 mg
Tabletoral8 mg
Tablet, film coatedoral2 mg/1
Tablet, film coatedoral8 mg/1
Tablet, film coatedoral4 mg/1
Prices
Unit descriptionCostUnit
Avandia 8 mg tablet8.69USD tablet
Avandia 4 mg tablet4.72USD tablet
Avandia 2 mg tablet3.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1328452 No1994-04-122011-04-12Canada
CA2143849 No2000-04-252013-09-01Canada
US5002953 No1994-09-172011-09-17Us
US5965584 No1996-06-192016-06-19Us
US6166042 No1996-06-192016-06-19Us
US6288095 Yes1997-08-112017-08-11Us
US7358366 Yes2000-10-192020-10-19Us
US8236345 No2002-10-072022-10-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point122-123 °CNot Available
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.038 mg/mLALOGPS
logP2.95ALOGPS
logP2.45ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)6.84ChemAxon
pKa (Strongest Basic)6.23ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area71.53 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.79 m3·mol-1ChemAxon
Polarizability37.8 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Manne Reddy, “Amorphous form of rosiglitazone maleate and process for preparation thereof.” U.S. Patent US20040242658, issued December 02, 2004.

US20040242658
General References
  1. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004 Jun;89(6):2728-35. [PubMed:15181049 ]
  2. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. [PubMed:17145742 ]
External Links
ATC CodesA10BD04A10BG02A10BD03
AHFS Codes
  • 68:20.28
PDB EntriesNot Available
FDA labelDownload (86.2 KB)
MSDSDownload (30 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Rosiglitazone.
AbciximabRosiglitazone may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Rosiglitazone can be increased when it is combined with Abiraterone.
AcenocoumarolRosiglitazone may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Rosiglitazone.
AcetohexamideRosiglitazone may increase the hypoglycemic activities of Acetohexamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Rosiglitazone.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Rosiglitazone.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Rosiglitazone.
AlprostadilAlprostadil may increase the anticoagulant activities of Rosiglitazone.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Rosiglitazone.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Rosiglitazone.
AmiodaroneThe metabolism of Rosiglitazone can be decreased when combined with Amiodarone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Rosiglitazone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Rosiglitazone.
AmoxapineAmoxapine may increase the hypoglycemic activities of Rosiglitazone.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Rosiglitazone.
AnagrelideAnagrelide may increase the anticoagulant activities of Rosiglitazone.
AncrodRosiglitazone may increase the anticoagulant activities of Ancrod.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Rosiglitazone.
Antithrombin III humanRosiglitazone may increase the anticoagulant activities of Antithrombin III human.
ApixabanRosiglitazone may increase the anticoagulant activities of Apixaban.
AprepitantThe metabolism of Rosiglitazone can be increased when combined with Aprepitant.
AprotininThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Aprotinin.
ArdeparinRosiglitazone may increase the anticoagulant activities of Ardeparin.
ArgatrobanRosiglitazone may increase the anticoagulant activities of Argatroban.
AripiprazoleThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Aripiprazole.
Arsenic trioxideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Arsenic trioxide.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Rosiglitazone resulting in a loss in efficacy.
ArticaineThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Asenapine.
AtazanavirThe serum concentration of Rosiglitazone can be increased when it is combined with Atazanavir.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Rosiglitazone.
AzelastineAzelastine may increase the anticoagulant activities of Rosiglitazone.
AzelastineThe metabolism of Azelastine can be decreased when combined with Rosiglitazone.
BecaplerminRosiglitazone may increase the anticoagulant activities of Becaplermin.
BendroflumethiazideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypoglycemic activities of Rosiglitazone.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Rosiglitazone.
BeraprostBeraprost may increase the anticoagulant activities of Rosiglitazone.
BeraprostThe metabolism of Beraprost can be decreased when combined with Rosiglitazone.
BetamethasoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Betamethasone.
BivalirudinRosiglitazone may increase the anticoagulant activities of Bivalirudin.
BrexpiprazoleThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Brexpiprazole.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Rosiglitazone.
BumetanideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Bumetanide.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Rosiglitazone.
BupropionThe metabolism of Bupropion can be decreased when combined with Rosiglitazone.
BuserelinThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Buserelin.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Rosiglitazone.
CaffeineThe metabolism of Caffeine can be decreased when combined with Rosiglitazone.
CangrelorCangrelor may increase the anticoagulant activities of Rosiglitazone.
CapecitabineThe metabolism of Rosiglitazone can be decreased when combined with Capecitabine.
CarbamazepineThe metabolism of Rosiglitazone can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Rosiglitazone.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Rosiglitazone.
CelecoxibThe metabolism of Rosiglitazone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Rosiglitazone can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Rosiglitazone.
CertoparinRosiglitazone may increase the anticoagulant activities of Certoparin.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Rosiglitazone.
ChlorothiazideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Chlorothiazide.
ChlorpropamideRosiglitazone may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Chlorthalidone.
CholecalciferolThe metabolism of Rosiglitazone can be decreased when combined with Cholecalciferol.
CholestyramineThe serum concentration of Rosiglitazone can be decreased when it is combined with Cholestyramine.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Rosiglitazone.
CilostazolCilostazol may increase the anticoagulant activities of Rosiglitazone.
CisaprideThe metabolism of Cisapride can be decreased when combined with Rosiglitazone.
CitalopramCitalopram may increase the hypoglycemic activities of Rosiglitazone.
Citric AcidRosiglitazone may increase the anticoagulant activities of Citric Acid.
ClomipramineClomipramine may increase the hypoglycemic activities of Rosiglitazone.
ClopidogrelClopidogrel may increase the anticoagulant activities of Rosiglitazone.
ClotrimazoleThe metabolism of Rosiglitazone can be decreased when combined with Clotrimazole.
ClozapineThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Clozapine.
ClozapineThe metabolism of Clozapine can be decreased when combined with Rosiglitazone.
CorticotropinThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Cortisone acetate.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Rosiglitazone.
CyclosporineThe metabolism of Rosiglitazone can be decreased when combined with Cyclosporine.
Cyproterone acetateThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Cyproterone acetate.
Dabigatran etexilateRosiglitazone may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Rosiglitazone.
DalteparinRosiglitazone may increase the anticoagulant activities of Dalteparin.
DanaparoidRosiglitazone may increase the anticoagulant activities of Danaparoid.
DanazolThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Danazol.
DapoxetineDapoxetine may increase the hypoglycemic activities of Rosiglitazone.
DapsoneThe metabolism of Dapsone can be decreased when combined with Rosiglitazone.
DarunavirThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Rosiglitazone.
DeferasiroxThe serum concentration of Rosiglitazone can be increased when it is combined with Deferasirox.
DefibrotideDefibrotide may increase the anticoagulant activities of Rosiglitazone.
DelavirdineThe metabolism of Rosiglitazone can be decreased when combined with Delavirdine.
DesirudinRosiglitazone may increase the anticoagulant activities of Desirudin.
DesogestrelThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Dexamethasone.
DextranRosiglitazone may increase the anticoagulant activities of Dextran.
Dextran 40Rosiglitazone may increase the anticoagulant activities of Dextran 40.
Dextran 70Rosiglitazone may increase the anticoagulant activities of Dextran 70.
Dextran 75Rosiglitazone may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Rosiglitazone.
DiazepamThe metabolism of Diazepam can be decreased when combined with Rosiglitazone.
DiazoxideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Diazoxide.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Rosiglitazone.
DicoumarolRosiglitazone may increase the anticoagulant activities of Dicoumarol.
DienogestThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Dienogest.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Rosiglitazone.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Rosiglitazone.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Rosiglitazone.
DipyridamoleDipyridamole may increase the anticoagulant activities of Rosiglitazone.
DisopyramideRosiglitazone may increase the hypoglycemic activities of Disopyramide.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Rosiglitazone.
DrospirenoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Drospirenone.
Edetic AcidRosiglitazone may increase the anticoagulant activities of Edetic Acid.
EdoxabanRosiglitazone may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Rosiglitazone can be decreased when combined with Efavirenz.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Rosiglitazone.
EnoxaparinRosiglitazone may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Rosiglitazone.
EpinastineEpinastine may increase the anticoagulant activities of Rosiglitazone.
EpinephrineThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Epinephrine.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Rosiglitazone.
EpoprostenolThe risk or severity of adverse effects can be increased when Rosiglitazone is combined with Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Rosiglitazone.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Rosiglitazone.
Erythrityl TetranitrateThe risk or severity of adverse effects can be increased when Erythrityl Tetranitrate is combined with Rosiglitazone.
EscitalopramEscitalopram may increase the hypoglycemic activities of Rosiglitazone.
EstradiolThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Estradiol.
EstradiolThe metabolism of Estradiol can be decreased when combined with Rosiglitazone.
Estrone sulfateThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Estrone sulfate.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Rosiglitazone.
Etacrynic acidThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Etacrynic acid.
Ethinyl EstradiolThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ethinyl Estradiol.
Ethyl biscoumacetateRosiglitazone may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethynodiol diacetateThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ethynodiol diacetate.
EtonogestrelThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Etonogestrel.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Rosiglitazone.
EtravirineThe metabolism of Rosiglitazone can be decreased when combined with Etravirine.
EverolimusThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Everolimus.
FelodipineThe metabolism of Rosiglitazone can be decreased when combined with Felodipine.
FenfluramineFenfluramine may increase the hypoglycemic activities of Rosiglitazone.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rosiglitazone.
FloxuridineThe metabolism of Rosiglitazone can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Rosiglitazone can be decreased when combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Fludrocortisone.
FluorouracilThe metabolism of Rosiglitazone can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the hypoglycemic activities of Rosiglitazone.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Rosiglitazone.
FluvastatinThe metabolism of Rosiglitazone can be decreased when combined with Fluvastatin.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Rosiglitazone.
Fondaparinux sodiumRosiglitazone may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Fosamprenavir.
FosphenytoinThe metabolism of Rosiglitazone can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Rosiglitazone.
FurosemideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Furosemide.
GemfibrozilThe metabolism of Rosiglitazone can be decreased when combined with Gemfibrozil.
GlibornurideRosiglitazone may increase the hypoglycemic activities of Glibornuride.
GliclazideRosiglitazone may increase the hypoglycemic activities of Gliclazide.
GlimepirideRosiglitazone may increase the hypoglycemic activities of Glimepiride.
GlipizideRosiglitazone may increase the hypoglycemic activities of Glipizide.
GliquidoneRosiglitazone may increase the hypoglycemic activities of Gliquidone.
GlisoxepideRosiglitazone may increase the hypoglycemic activities of Glisoxepide.
GlyburideRosiglitazone may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Rosiglitazone.
HeparinRosiglitazone may increase the anticoagulant activities of Heparin.
HirulogRosiglitazone may increase the anticoagulant activities of Hirulog.
HistrelinThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Histrelin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Rosiglitazone.
HydrochlorothiazideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydroxyprogesterone caproate.
IbudilastIbudilast may increase the anticoagulant activities of Rosiglitazone.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Rosiglitazone.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Rosiglitazone.
IfenprodilIfenprodil may increase the anticoagulant activities of Rosiglitazone.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Rosiglitazone.
IloperidoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Iloperidone.
IloprostIloprost may increase the anticoagulant activities of Rosiglitazone.
IloprostThe risk or severity of adverse effects can be increased when Rosiglitazone is combined with Iloprost.
IndalpineIndalpine may increase the hypoglycemic activities of Rosiglitazone.
IndapamideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Indapamide.
IndinavirThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Indinavir.
Insulin AspartRosiglitazone may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirRosiglitazone may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineRosiglitazone may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineRosiglitazone may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanRosiglitazone may increase the hypoglycemic activities of Insulin Human.
Insulin LisproRosiglitazone may increase the hypoglycemic activities of Insulin Lispro.
Insulin PorkThe risk or severity of adverse effects can be increased when Insulin Pork is combined with Rosiglitazone.
IproclozideIproclozide may increase the hypoglycemic activities of Rosiglitazone.
IproniazidIproniazid may increase the hypoglycemic activities of Rosiglitazone.
IrbesartanThe metabolism of Rosiglitazone can be decreased when combined with Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Rosiglitazone.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Rosiglitazone.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Rosiglitazone.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Rosiglitazone.
KetamineThe metabolism of Ketamine can be decreased when combined with Rosiglitazone.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Rosiglitazone.
KetoconazoleThe metabolism of Rosiglitazone can be decreased when combined with Ketoconazole.
LanreotideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lanreotide.
LanreotideRosiglitazone may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Rosiglitazone.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Rosiglitazone.
LeflunomideThe metabolism of Rosiglitazone can be decreased when combined with Leflunomide.
LepirudinRosiglitazone may increase the anticoagulant activities of Lepirudin.
LeuprolideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Rosiglitazone.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Rosiglitazone.
LevonorgestrelThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Levonorgestrel.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Rosiglitazone.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Rosiglitazone.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Rosiglitazone.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Rosiglitazone.
LoperamideThe metabolism of Loperamide can be decreased when combined with Rosiglitazone.
LopinavirThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Rosiglitazone.
LosartanThe metabolism of Rosiglitazone can be decreased when combined with Losartan.
LovastatinThe metabolism of Rosiglitazone can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Rosiglitazone.
LumacaftorThe serum concentration of Rosiglitazone can be decreased when it is combined with Lumacaftor.
LurasidoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lurasidone.
MebanazineMebanazine may increase the hypoglycemic activities of Rosiglitazone.
MecaserminRosiglitazone may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Rosiglitazone.
Megestrol acetateThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Megestrol acetate.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Rosiglitazone.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Rosiglitazone.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Rosiglitazone.
MestranolThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Mestranol.
MethadoneThe metabolism of Methadone can be decreased when combined with Rosiglitazone.
MethotrimeprazineThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methyclothiazide.
Methylene blueMethylene blue may increase the hypoglycemic activities of Rosiglitazone.
MethylprednisoloneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methylprednisolone.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Rosiglitazone.
MetolazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Rosiglitazone.
MifepristoneThe serum concentration of Rosiglitazone can be increased when it is combined with Mifepristone.
MifepristoneRosiglitazone may increase the hypoglycemic activities of Mifepristone.
MilnacipranMilnacipran may increase the hypoglycemic activities of Rosiglitazone.
MilrinoneMilrinone may increase the anticoagulant activities of Rosiglitazone.
MinaprineMinaprine may increase the hypoglycemic activities of Rosiglitazone.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Rosiglitazone.
MoclobemideMoclobemide may increase the hypoglycemic activities of Rosiglitazone.
MorphineThe metabolism of Morphine can be decreased when combined with Rosiglitazone.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Rosiglitazone.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Rosiglitazone.
NadroparinRosiglitazone may increase the anticoagulant activities of Nadroparin.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Rosiglitazone.
NaproxenThe metabolism of Naproxen can be decreased when combined with Rosiglitazone.
NateglinideRosiglitazone may increase the hypoglycemic activities of Nateglinide.
NCX 4016NCX 4016 may increase the anticoagulant activities of Rosiglitazone.
NelfinavirThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Nelfinavir.
NiacinThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Niacin.
NialamideNialamide may increase the hypoglycemic activities of Rosiglitazone.
NicardipineThe metabolism of Rosiglitazone can be decreased when combined with Nicardipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Rosiglitazone.
NilotinibThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Nilotinib.
NimesulideNimesulide may increase the anticoagulant activities of Rosiglitazone.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Rosiglitazone.
NorethisteroneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Norgestimate.
OctamoxinOctamoxin may increase the hypoglycemic activities of Rosiglitazone.
OctreotideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Octreotide.
OctreotideRosiglitazone may increase the hypoglycemic activities of Octreotide.
OlanzapineOlanzapine may increase the hypoglycemic activities of Rosiglitazone.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Rosiglitazone.
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Rosiglitazone.
OmeprazoleThe metabolism of Rosiglitazone can be decreased when combined with Omeprazole.
OtamixabanRosiglitazone may increase the anticoagulant activities of Otamixaban.
OxandroloneOxandrolone may increase the hypoglycemic activities of Rosiglitazone.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Rosiglitazone.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Rosiglitazone.
PaliperidoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Paliperidone.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Rosiglitazone.
PargylinePargyline may increase the hypoglycemic activities of Rosiglitazone.
ParoxetineParoxetine may increase the hypoglycemic activities of Rosiglitazone.
PasireotideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Pasireotide.
PasireotideRosiglitazone may increase the hypoglycemic activities of Pasireotide.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Rosiglitazone.
PegvisomantPegvisomant may increase the hypoglycemic activities of Rosiglitazone.
PentamidineThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Pentamidine.
PentamidineRosiglitazone may increase the hypoglycemic activities of Pentamidine.
Pentosan PolysulfateRosiglitazone may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Rosiglitazone.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Rosiglitazone.
PhenelzinePhenelzine may increase the hypoglycemic activities of Rosiglitazone.
PhenindioneRosiglitazone may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the hypoglycemic activities of Rosiglitazone.
PhenobarbitalThe metabolism of Rosiglitazone can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Rosiglitazone.
PhenprocoumonRosiglitazone may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe metabolism of Rosiglitazone can be increased when combined with Phenytoin.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Rosiglitazone.
PiperazineThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Pipotiazine.
PirlindolePirlindole may increase the hypoglycemic activities of Rosiglitazone.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Rosiglitazone.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Rosiglitazone.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Rosiglitazone.
PolythiazideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Polythiazide.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Rosiglitazone.
PrasugrelPrasugrel may increase the anticoagulant activities of Rosiglitazone.
PrednisoloneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Prednisone.
PregabalinPregabalin may increase the fluid retaining activities of Rosiglitazone.
PrimidoneThe metabolism of Rosiglitazone can be increased when combined with Primidone.
ProgesteroneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Progesterone.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Rosiglitazone.
PropofolThe metabolism of Propofol can be decreased when combined with Rosiglitazone.
Protein CRosiglitazone may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeRosiglitazone may increase the anticoagulant activities of Protocatechualdehyde.
PyrimethamineThe metabolism of Rosiglitazone can be decreased when combined with Pyrimethamine.
QuetiapineThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Quetiapine.
QuinethazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Quinethazone.
QuinidineThe metabolism of Quinidine can be decreased when combined with Rosiglitazone.
QuinineRosiglitazone may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Rosiglitazone can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Rosiglitazone can be decreased when combined with Rabeprazole.
RasagilineRasagiline may increase the hypoglycemic activities of Rosiglitazone.
RepaglinideRosiglitazone may increase the hypoglycemic activities of Repaglinide.
ResveratrolResveratrol may increase the anticoagulant activities of Rosiglitazone.
ReviparinRosiglitazone may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Rosiglitazone.
RifampicinThe metabolism of Rosiglitazone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Rosiglitazone can be increased when combined with Rifapentine.
RiociguatThe metabolism of Riociguat can be decreased when combined with Rosiglitazone.
RisperidoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ritonavir.
RivaroxabanRosiglitazone may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Rosiglitazone.
SafrazineSafrazine may increase the hypoglycemic activities of Rosiglitazone.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Rosiglitazone.
SaquinavirThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Saquinavir.
SCH-530348SCH-530348 may increase the anticoagulant activities of Rosiglitazone.
SecobarbitalThe metabolism of Rosiglitazone can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypoglycemic activities of Rosiglitazone.
SelegilineThe metabolism of Selegiline can be decreased when combined with Rosiglitazone.
SelexipagThe metabolism of Selexipag can be decreased when combined with Rosiglitazone.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Rosiglitazone.
SertralineSertraline may increase the hypoglycemic activities of Rosiglitazone.
SevofluraneSevoflurane may increase the anticoagulant activities of Rosiglitazone.
SildenafilThe metabolism of Rosiglitazone can be decreased when combined with Sildenafil.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Rosiglitazone.
SirolimusThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Sirolimus.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Rosiglitazone.
SorafenibThe metabolism of Rosiglitazone can be decreased when combined with Sorafenib.
SRT501SRT501 may increase the anticoagulant activities of Rosiglitazone.
StanozololStanozolol may increase the hypoglycemic activities of Rosiglitazone.
StiripentolThe metabolism of Rosiglitazone can be decreased when combined with Stiripentol.
SulfadiazineRosiglitazone may increase the hypoglycemic activities of Sulfadiazine.
SulfadiazineThe metabolism of Rosiglitazone can be decreased when combined with Sulfadiazine.
SulfamethoxazoleRosiglitazone may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamethoxazoleThe metabolism of Rosiglitazone can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Rosiglitazone.
SulfisoxazoleRosiglitazone may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Rosiglitazone can be decreased when combined with Sulfisoxazole.
SulodexideRosiglitazone may increase the anticoagulant activities of Sulodexide.
SunitinibRosiglitazone may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Tacrolimus.
TamoxifenThe metabolism of Rosiglitazone can be decreased when combined with Tamoxifen.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Rosiglitazone.
TemazepamThe metabolism of Temazepam can be decreased when combined with Rosiglitazone.
TemsirolimusThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Temsirolimus.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Rosiglitazone.
TeriflunomideThe metabolism of Rosiglitazone can be decreased when combined with Teriflunomide.
TesmilifeneTesmilifene may increase the anticoagulant activities of Rosiglitazone.
TestosteroneTestosterone may increase the hypoglycemic activities of Rosiglitazone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Rosiglitazone.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Rosiglitazone.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Rosiglitazone.
TicagrelorThe metabolism of Rosiglitazone can be decreased when combined with Ticagrelor.
TiclopidineTiclopidine may increase the anticoagulant activities of Rosiglitazone.
TipranavirThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Tipranavir.
TirofibanTirofiban may increase the anticoagulant activities of Rosiglitazone.
TolazamideRosiglitazone may increase the hypoglycemic activities of Tolazamide.
TolbutamideRosiglitazone may increase the hypoglycemic activities of Tolbutamide.
TolbutamideThe metabolism of Rosiglitazone can be decreased when combined with Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Rosiglitazone.
TorasemideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Torasemide.
TorasemideThe metabolism of Torasemide can be decreased when combined with Rosiglitazone.
TranilastTranilast may increase the anticoagulant activities of Rosiglitazone.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Rosiglitazone.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Rosiglitazone.
TrapidilTrapidil may increase the anticoagulant activities of Rosiglitazone.
TrazodoneTrazodone may increase the hypoglycemic activities of Rosiglitazone.
TreprostinilThe risk or severity of adverse effects can be increased when Rosiglitazone is combined with Treprostinil.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Rosiglitazone.
TriamcinoloneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Triamcinolone.
TrichlormethiazideThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Trichlormethiazide.
TriflusalTriflusal may increase the anticoagulant activities of Rosiglitazone.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Rosiglitazone.
TrimethoprimThe metabolism of Rosiglitazone can be decreased when combined with Trimethoprim.
TriptorelinThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Triptorelin.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Rosiglitazone.
Valproic AcidThe metabolism of Rosiglitazone can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Rosiglitazone can be decreased when combined with Valsartan.
VerapamilThe metabolism of Verapamil can be decreased when combined with Rosiglitazone.
VilazodoneVilazodone may increase the hypoglycemic activities of Rosiglitazone.
VorapaxarVorapaxar may increase the anticoagulant activities of Rosiglitazone.
VoriconazoleThe metabolism of Rosiglitazone can be decreased when combined with Voriconazole.
VorinostatThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Vorinostat.
VortioxetineVortioxetine may increase the hypoglycemic activities of Rosiglitazone.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Rosiglitazone.
WarfarinRosiglitazone may increase the anticoagulant activities of Warfarin.
XimelagatranRosiglitazone may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Rosiglitazone can be decreased when combined with Zafirlukast.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Rosiglitazone.
ZimelidineZimelidine may increase the hypoglycemic activities of Rosiglitazone.
ZiprasidoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ziprasidone.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Rosiglitazone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Su JL, Winegar DA, Wisely GB, Sigel CS, Hull-Ryde EA: Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro. Hybridoma. 1999 Jun;18(3):273-80. [PubMed:10475242 ]
  2. Rieusset J, Auwerx J, Vidal H: Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun. 1999 Nov;265(1):265-71. [PubMed:10548525 ]
  3. Kameda N, Okuya S, Oka Y: [Rosiglitazone (BRL-49653)]. Nihon Rinsho. 2000 Feb;58(2):401-4. [PubMed:10707565 ]
  4. Johnson BA, Wilson EM, Li Y, Moller DE, Smith RG, Zhou G: Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol. 2000 Apr 28;298(2):187-94. [PubMed:10764590 ]
  5. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, Leff T: Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes. 2000 Apr;49(4):539-47. [PubMed:10871190 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Very long-chain fatty acid-coa ligase activity
Specific Function:
Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates.
Gene Name:
ACSL4
Uniprot ID:
O60488
Molecular Weight:
79187.38 Da
References
  1. Askari B, Kanter JE, Sherrid AM, Golej DL, Bender AT, Liu J, Hsueh WA, Beavo JA, Coleman RA, Bornfeldt KE: Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages. Diabetes. 2007 Apr;56(4):1143-52. Epub 2007 Jan 26. [PubMed:17259370 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I: Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos. 2004 Mar;32(3):291-4. [PubMed:14977862 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 03:31